Shares of Poniard Pharmaceuticals Inc. tumbled 76 percent on disappointing data from its Phase III trial of picoplatin in small-cell lung cancer, news that's certain to hamper ongoing discussions for a much-needed partnership. (BioWorld Today) Read More
